Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop

Uwe Platzbecker; Valeria Santini; Ghulam J Mufti; Claudia Haferlach; Jaroslaw P Maciejewski; Sophie Park; Francesc Solé; Arjan A van de Loosdrecht; Detlef Haase

doi:10.1016/j.leukres.2011.11.005

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop

Leuk Res. 2012 Mar;36(3):264-70. doi: 10.1016/j.leukres.2011.11.005. Epub 2011 Dec 3.

Authors

Uwe Platzbecker¹, Valeria Santini, Ghulam J Mufti, Claudia Haferlach, Jaroslaw P Maciejewski, Sophie Park, Francesc Solé, Arjan A van de Loosdrecht, Detlef Haase

Affiliation

¹ Universitätsklinikum Carl-Gustav-Carus, Medizinische Klinik I, Dresden, Germany. [email protected]

PMID: 22137318
DOI: 10.1016/j.leukres.2011.11.005

Abstract

Several new treatments for myelodysplastic syndromes (MDS) have recently become available, or are in development. Patients who could benefit from active treatment must be effectively identified and followed up. Therefore, guidelines for the diagnosis and prognostic evaluation of MDS need to be kept up to date with technological and scientific advances. An expert workshop was convened to review currently available and emerging diagnostic technologies and developments in prognostic classification systems, to ensure appropriate management of individual patients. The panel also provided suggestions to ensure adherence to guidelines and highlighted the mandatory requirement for cytogenetic evaluation in patients with MDS.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Consensus*
Disease Management
Guidelines as Topic*
Humans
Myelodysplastic Syndromes / diagnosis*
Myelodysplastic Syndromes / therapy*
Prognosis